Molecular Response | GenomeWeb

Molecular Response

Crown is acquiring Molecular Response's existing PDX models and 8,000 viable human tumors for model development.

NEW YORK (GenomeWeb) – Therapeutic research firm Boston Strategics and molecular diagnostic services shop Molecular Response have agreed to design and manage drug development programs together with the aim of identifying subpopulations of best responders to treatments and improving their probabil

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Transparent and Molecular Response today announced the extension of validation studies and the execution of a long-term collaboration agreement.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Gen-Probe disclosed in its annual 2011 earnings document that it has lost almost $41 million in its investment in Pacific Biosciences as of the end of 2011.

Pharmaceutical firm SuperGen will have limited access to Molecular Response's "living" cell bank of primary tumor cells, high-content imaging, and molecular characterization platforms.

The R&D deal targets oncology and cardiovascular disease.

The bank, formerly owned by Oncotech, contains more than 144,000 discrete cancer samples.

People in the News


David Ledbetter, Thomas Broudy

People in the News


RainDance taps Richard Lussier and Ingrid Choupin for sales positions; Molecular Response hires Thomas Broudy as chief scientific officer and Richard Scuderi as medical director.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.